Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryosuke Saigusa

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Dermatology|April 23, 2017
Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosisTakuya Miyagawa, Yoshihide Asano, Yuka de Mestier, et al.
Rheumatology (Oxford, England)|December 26, 2014
Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosisKaname Akamata, Yoshihide Asano, Takashi Taniguchi, et al.
The Journal of Dermatology|January 19, 2016
Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosisKouki Nakamura, Yoshihide Asano, Takashi Taniguchi, et al.
The Journal of Dermatology|October 6, 2018
Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational studyHayakazu Sumida, Yoshihide Asano, Zenshiro Tamaki, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 31, 2017
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic SclerosisTakemichi Fukasawa, Ayumi Yoshizaki, Satoshi Ebata, et al.
The Journal of Dermatology|July 28, 2018
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung diseaseHiroko Numajiri, Ayumi Yoshizaki, Takemichi Fukasawa, et al.
Nature Communications|December 16, 2014
Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosisShinji Noda, Yoshihide Asano, Satoshi Nishimura, et al.
The Journal of Dermatology|February 28, 2015
Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosisRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
Frontiers in Cardiovascular Medicine|January 31, 2022
Chemokine Receptor Activation Enhances Memory B Cell Class Switching Linked to IgE Sensitization to Alpha Gal and Cardiovascular DiseaseTanyaporn Pattarabanjird, Jeffrey M Wilson, Loren D Erickson, et al.
International Journal of Molecular Sciences|September 9, 2022
Sex Differences in Coronary Artery Disease and Diabetes Revealed by scRNA-Seq and CITE-Seq of Human CD4+ T CellsRyosuke Saigusa, Jenifer Vallejo, Rishab Gulati, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Dermatology|April 23, 2017
Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosisTakuya Miyagawa, Yoshihide Asano, Yuka de Mestier, et al.
Rheumatology (Oxford, England)|December 26, 2014
Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosisKaname Akamata, Yoshihide Asano, Takashi Taniguchi, et al.
The Journal of Dermatology|January 19, 2016
Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosisKouki Nakamura, Yoshihide Asano, Takashi Taniguchi, et al.
The Journal of Dermatology|October 6, 2018
Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational studyHayakazu Sumida, Yoshihide Asano, Zenshiro Tamaki, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 31, 2017
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic SclerosisTakemichi Fukasawa, Ayumi Yoshizaki, Satoshi Ebata, et al.
The Journal of Dermatology|July 28, 2018
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung diseaseHiroko Numajiri, Ayumi Yoshizaki, Takemichi Fukasawa, et al.
Nature Communications|December 16, 2014
Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosisShinji Noda, Yoshihide Asano, Satoshi Nishimura, et al.
The Journal of Dermatology|February 28, 2015
Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosisRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
Frontiers in Cardiovascular Medicine|January 31, 2022
Chemokine Receptor Activation Enhances Memory B Cell Class Switching Linked to IgE Sensitization to Alpha Gal and Cardiovascular DiseaseTanyaporn Pattarabanjird, Jeffrey M Wilson, Loren D Erickson, et al.
International Journal of Molecular Sciences|September 9, 2022
Sex Differences in Coronary Artery Disease and Diabetes Revealed by scRNA-Seq and CITE-Seq of Human CD4+ T CellsRyosuke Saigusa, Jenifer Vallejo, Rishab Gulati, et al.
Pageof 6